Cargando…
Cost-Effectiveness Analysis from a Randomized Controlled Trial of Tailored Exercise Prescription for Women with Breast Cancer with 8-Year Follow-Up
Studies show conflicting results on whether exercise interventions to improve outcomes for women with breast cancer are cost-effective. We modelled the long-term cost-effectiveness of the Exercise for Health intervention compared with usual care. A lifetime Markov cohort model for women with early b...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7699530/ https://www.ncbi.nlm.nih.gov/pubmed/33228174 http://dx.doi.org/10.3390/ijerph17228608 |
_version_ | 1783616069505646592 |
---|---|
author | Gordon, Louisa G. Eakin, Elizabeth G. Spence, Rosalind R. Pyke, Christopher Bashford, John Saunders, Christobel Hayes, Sandra C. |
author_facet | Gordon, Louisa G. Eakin, Elizabeth G. Spence, Rosalind R. Pyke, Christopher Bashford, John Saunders, Christobel Hayes, Sandra C. |
author_sort | Gordon, Louisa G. |
collection | PubMed |
description | Studies show conflicting results on whether exercise interventions to improve outcomes for women with breast cancer are cost-effective. We modelled the long-term cost-effectiveness of the Exercise for Health intervention compared with usual care. A lifetime Markov cohort model for women with early breast cancer was constructed taking a societal perspective. Data were obtained from trial, epidemiological, quality of life, and healthcare cost reports. Outcomes were calculated from 5000 Monte Carlo simulations, and one-way and probabilistic sensitivity analyses. Over the cohort’s remaining life, the incremental cost for the exercise versus usual care groups were $7409 and quality-adjusted life years (QALYs) gained were 0.35 resulting in an incremental cost per QALY ratio of AU$21,247 (95% Uncertainty Interval (UI): Dominant, AU$31,398). The likelihood that the exercise intervention was cost-effective at acceptable levels was 93.0%. The incremental cost per life year gained was AU$8894 (95% UI Dominant, AU$11,769) with a 99.4% probability of being cost effective. Findings were most sensitive to the probability of recurrence in the exercise and usual care groups, followed by the costs of out-of-pocket expenses and the model starting age. This exercise intervention for women after early-stage breast cancer is cost-effective and would be a sound investment of healthcare resources. |
format | Online Article Text |
id | pubmed-7699530 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-76995302020-11-29 Cost-Effectiveness Analysis from a Randomized Controlled Trial of Tailored Exercise Prescription for Women with Breast Cancer with 8-Year Follow-Up Gordon, Louisa G. Eakin, Elizabeth G. Spence, Rosalind R. Pyke, Christopher Bashford, John Saunders, Christobel Hayes, Sandra C. Int J Environ Res Public Health Article Studies show conflicting results on whether exercise interventions to improve outcomes for women with breast cancer are cost-effective. We modelled the long-term cost-effectiveness of the Exercise for Health intervention compared with usual care. A lifetime Markov cohort model for women with early breast cancer was constructed taking a societal perspective. Data were obtained from trial, epidemiological, quality of life, and healthcare cost reports. Outcomes were calculated from 5000 Monte Carlo simulations, and one-way and probabilistic sensitivity analyses. Over the cohort’s remaining life, the incremental cost for the exercise versus usual care groups were $7409 and quality-adjusted life years (QALYs) gained were 0.35 resulting in an incremental cost per QALY ratio of AU$21,247 (95% Uncertainty Interval (UI): Dominant, AU$31,398). The likelihood that the exercise intervention was cost-effective at acceptable levels was 93.0%. The incremental cost per life year gained was AU$8894 (95% UI Dominant, AU$11,769) with a 99.4% probability of being cost effective. Findings were most sensitive to the probability of recurrence in the exercise and usual care groups, followed by the costs of out-of-pocket expenses and the model starting age. This exercise intervention for women after early-stage breast cancer is cost-effective and would be a sound investment of healthcare resources. MDPI 2020-11-19 2020-11 /pmc/articles/PMC7699530/ /pubmed/33228174 http://dx.doi.org/10.3390/ijerph17228608 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Gordon, Louisa G. Eakin, Elizabeth G. Spence, Rosalind R. Pyke, Christopher Bashford, John Saunders, Christobel Hayes, Sandra C. Cost-Effectiveness Analysis from a Randomized Controlled Trial of Tailored Exercise Prescription for Women with Breast Cancer with 8-Year Follow-Up |
title | Cost-Effectiveness Analysis from a Randomized Controlled Trial of Tailored Exercise Prescription for Women with Breast Cancer with 8-Year Follow-Up |
title_full | Cost-Effectiveness Analysis from a Randomized Controlled Trial of Tailored Exercise Prescription for Women with Breast Cancer with 8-Year Follow-Up |
title_fullStr | Cost-Effectiveness Analysis from a Randomized Controlled Trial of Tailored Exercise Prescription for Women with Breast Cancer with 8-Year Follow-Up |
title_full_unstemmed | Cost-Effectiveness Analysis from a Randomized Controlled Trial of Tailored Exercise Prescription for Women with Breast Cancer with 8-Year Follow-Up |
title_short | Cost-Effectiveness Analysis from a Randomized Controlled Trial of Tailored Exercise Prescription for Women with Breast Cancer with 8-Year Follow-Up |
title_sort | cost-effectiveness analysis from a randomized controlled trial of tailored exercise prescription for women with breast cancer with 8-year follow-up |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7699530/ https://www.ncbi.nlm.nih.gov/pubmed/33228174 http://dx.doi.org/10.3390/ijerph17228608 |
work_keys_str_mv | AT gordonlouisag costeffectivenessanalysisfromarandomizedcontrolledtrialoftailoredexerciseprescriptionforwomenwithbreastcancerwith8yearfollowup AT eakinelizabethg costeffectivenessanalysisfromarandomizedcontrolledtrialoftailoredexerciseprescriptionforwomenwithbreastcancerwith8yearfollowup AT spencerosalindr costeffectivenessanalysisfromarandomizedcontrolledtrialoftailoredexerciseprescriptionforwomenwithbreastcancerwith8yearfollowup AT pykechristopher costeffectivenessanalysisfromarandomizedcontrolledtrialoftailoredexerciseprescriptionforwomenwithbreastcancerwith8yearfollowup AT bashfordjohn costeffectivenessanalysisfromarandomizedcontrolledtrialoftailoredexerciseprescriptionforwomenwithbreastcancerwith8yearfollowup AT saunderschristobel costeffectivenessanalysisfromarandomizedcontrolledtrialoftailoredexerciseprescriptionforwomenwithbreastcancerwith8yearfollowup AT hayessandrac costeffectivenessanalysisfromarandomizedcontrolledtrialoftailoredexerciseprescriptionforwomenwithbreastcancerwith8yearfollowup |